Clinical Trials
Saturday, June 2nd, 2012
Stroke.ahajournals.org: May 24, 2012 Background and Purpose—The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of candesartan in acute stroke. In the present analysis we aim to investigate the effect of change in blood pressure during the first 2 days of stroke on the risk of early adverse events and poor outcome. Methods—SCAST was a […]
Clinical Trials
Saturday, June 2nd, 2012
Irinnews.org: LONDON, 24 May 2012 (IRIN) – The more medical successes there are, the more it costs to find the next one, prompting donors to demand more from researchers carrying out large-scale trials of drugs, vaccines and global health impacts. “As a funder, I hate clinical trial applications,” said Jimmy Whitworth, head of international activities at […]
Therapies
Saturday, June 2nd, 2012
Stroke.ahajournals.org: April 24, 2012. Background and Purpose—The aim of this study was to analyze epileptic seizures and their impact on outcome in patients with stroke treated with endovascular therapy. Methods—From December 1992 to December 2010 we managed 805 patients with stroke with endovascular therapy. Epileptic seizures, bleeding complications, and 3-month outcomes were recorded prospectively. Outcomes of […]
Therapies
Saturday, June 2nd, 2012
Stroke.ahajournals.org: April 24, 2012 Progress in Sonothrombolysis for the Treatment of Stroke In 1974, Sobbe et al1 applied 26.5-kHz ultrasound (US) to recanalize thrombosed iliofemoral arteries in dogs with minimal complications. These pioneer efforts were followed by studies showing that catheter-based or transcutaneous US can enhance the effect of fibrinolytic agents in recanalizing thrombosed arteries,2–8 thus paving the […]
Therapies
Saturday, June 2nd, 2012
Stroke.ahajournals.org: April 10, 2012. Background and Purpose—Experimental data suggest a negative interaction between x-ray contrast agents and fibrinolytic efficacy of recombinant tissue-type plasminogen activator (rtPA). We hypothesized that the application of a contrast agent before intravenous thrombolysis with rtPA reduces its clinical efficacy in acute ischemic stroke. Methods—We retrospectively studied consecutive ischemic stroke patients receiving contrast […]
Therapies
Saturday, June 2nd, 2012
Stroke.ahajournals.org: March 22, 2012 Background and Purpose—Studies suggest a protective role for statins after intracerebral hemorrhage, but many failed to assess statin discontinuation, did not include postdischarge outcomes, or did not account for withdrawal of care. We studied the relationship between preintracerebral hemorrhage statin use and in-hospital statin discontinuation on stroke severity and 30-day mortality. […]
Therapies
Saturday, June 2nd, 2012
Stroke.ahajournals.org: March 22, 2012. Background and Purpose—The publication of the European Cooperative Acute Stroke Study (ECASS III) expanded the treatment time to thrombolysis for acute ischemic stroke from 3 to 4.5 hours from symptom onset. The impact of the expanded time window on treatment rates has not been comprehensively evaluated in a population-based study. Methods—All patients […]
Atrial Fibrillation
Saturday, June 2nd, 2012
Stroke.ahajournals.org: May 24, 2012 Background and Purpose—Atrial fibrillation has been considered a risk factor for poor outcome from acute stroke and may influence response to thrombolysis, although supporting data are limited due to potential confounding with age and stroke severity. Method—We assessed the association of atrial fibrillation and thrombolysis exposure with the modified Rankin Scale score […]
Guidelines
Saturday, June 2nd, 2012
A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Stroke.ahajournals.org: May 24, 2012. Background and Purpose—Current US guideline statements regarding primary and secondary cardiovascular risk prediction and prevention use absolute risk estimates to identify patients who are at high risk for vascular disease events and who may benefit from specific preventive interventions. These […]
